Where does Supernus Pharmaceuticals's cash flow data come from?

Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$38.55M-152%	$73.87M+5,513%	$1.32M-97.8%	$60.71M+13.6%
Depreciation and amortization	$91.56M+13.9%	$80.41M-5.2%	$84.86M-0.8%	$85.54M+162%
Stock-based compensation	$33.05M+19.1%	$27.76M+3.7%	$26.76M+52.3%	$17.57M-1.9%
Deferred income taxes	$5.21M+126%	-$20.14M+21.7%	-$25.71M+2.3%	-$26.32M—
Impairment charges	$0—	$0—	——	$0—
Change in accounts receivable	$22.3M+1,173%	-$2.08M—	——	$16.37M—
Change in inventories	$7.5M+147%	-$15.81M-159%	-$6.11M-134%	$17.86M+22.5%
Change in accounts payable	-$24.57M-63.6%	-$15.02M+58.6%	-$36.29M-89.4%	-$19.16M-205%
Change in other assets	$13.18M-34.4%	$20.08M—	——	-$12.3M—
Other working capital changes	——	——	$606K—	——
Net gains (losses) on investments	——	$9K—	$0—	——
Non-cash operating lease expense	——	$5.45M-16.2%	$6.5M—	——
Change in fair value of contingent consideration	$25.42M+493%	-$6.47M-326%	-$1.52M-197%	-$510K—
Net cash from operating activities	——	$171.95M—	——	$116.83M-11.0%
Capital expenditures	$1.34M+84.6%	$725K+23.5%	$587K—	——
Purchases of investments	$475.94M-30.8%	$688.01M+577%	$101.62M-75.0%	$406.99M—
Proceeds from maturities/sales of investments	$774.48M+55.2%	$498.87M+34.5%	$370.9M+94.5%	$190.74M-64.0%
Net cash from investing activities	——	-$189.87M—	——	-$216.66M—
Proceeds from issuance of common stock	$37.62M+152%	$14.91M+126%	$6.61M-46.8%	$12.42M+75.1%
Taxes paid for net share settlement	$4.23M+55.8%	$2.72M+36.4%	$1.99M—	$0—
Other financing activities	$24.26M—	$0—	$0—	——
Net cash from financing activities	$9.13M-25.1%	$12.19M+103%	-$398.97M—	——
Net increase (decrease) in cash	——	——	-$18.07M—	——
Income taxes paid	$16.05M-69.9%	$53.25M+45.5%	$36.6M+126%	$16.2M-35.7%
Accrued product returns and rebates	-$7.61M—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$13.18M-34.4%	$20.08M—	——	-$12.3M—
Inventory write-downs	——	$8.91M+11.0%	$8.02M-23.2%	$10.44M—
Investment Income Net Amortization Of Discount And Premium	——	——	——	-$3.23M-673%
Operating lease right-of-use asset amortization	——	$5.45M-16.2%	$6.5M—	——
Other Noncash Income (Expense)	——	——	$606K—	——
Payment For Contingent Consideration Liability Operating Activities	——	$0—	$0—	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$774.48M+55.2%	$498.87M—	——	$190.74M—
Income Taxes Paid, Net	$16.05M-69.9%	$53.25M+45.5%	$36.6M+126%	$16.2M-35.7%
Free cash flow	——	$171.23M—	——	$116.41M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Supernus Pharmaceuticals's cash flow data come from?: Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.